Clinical Trial Update: Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction [Phase 1]

View source ↗

Summary

This clinical trial update summarizes a Phase 1 study of Imatinib Mesylate in patients with advanced cancer and liver dysfunction, which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia Accelerated Phase
• Chronic Myeloid Leukemia Bcr-abl1 Positive
• Diffuse Large B-cell Lymphoma
• Gastrointestinal Stromal Tumor
• Hodgkin Lymphoma
• T-cell Non-hodgkin Lymphoma
• Undifferentiated Leukemia

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Phase 1 | Status: COMPLETED